CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China; Department of Urology, Peking University First Hospital, Beijing 100034, China; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.
Laboratory of Chemical Biology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Cancer Cell. 2016 Sep 12;30(3):474-484. doi: 10.1016/j.ccell.2016.08.003.
In the cytoplasm of virtually all clear-cell renal cell carcinoma (ccRCC), speckle-type POZ protein (SPOP) is overexpressed and misallocated, which may induce proliferation and promote kidney tumorigenesis. In normal cells, however, SPOP is located in the nucleus and induces apoptosis. Here we show that a structure-based design and subsequent hit optimization yield small molecules that can inhibit the SPOP-substrate protein interaction and can suppress oncogenic SPOP-signaling pathways. These inhibitors kill human ccRCC cells that are dependent on oncogenic cytoplasmic SPOP. Notably, these inhibitors minimally affect the viability of other cells in which SPOP is not accumulated in the cytoplasm. Our findings validate the SPOP-substrate protein interaction as an attractive target specific to ccRCC that may yield novel drug discovery efforts.
在几乎所有透明细胞肾细胞癌 (ccRCC) 的细胞质中,点状结构域 POZ 蛋白 (SPOP) 过表达和错位,这可能诱导增殖并促进肾肿瘤发生。然而,在正常细胞中,SPOP 位于细胞核中并诱导细胞凋亡。在这里,我们展示了一种基于结构的设计和随后的命中优化,可以产生抑制 SPOP-底物蛋白相互作用的小分子,并可以抑制致癌的 SPOP 信号通路。这些抑制剂可以杀死依赖致癌性细胞质 SPOP 的人 ccRCC 细胞。值得注意的是,这些抑制剂对其他 SPOP 未在细胞质中积累的细胞的活力影响很小。我们的研究结果验证了 SPOP-底物蛋白相互作用作为一种有吸引力的特定于 ccRCC 的靶点,可能会产生新的药物发现努力。